Pfizer
Pfizer pays $63m for generics portfolio
January 5, 2011Sales and Marketing Akorn, Akorn-Strides, Pfizer, Strides Arcolab, generics, injectables
Pfizer has bolstered its generics portfolio, paying around $63 million for 22 drugs. The company will buy 16 Abbreviated New …
VTE trial boost for Pfizer and BMS’ apixaban
December 31, 2010Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism
Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …
Pfizer expands Lipitor recall
December 24, 2010Manufacturing and Production Lipitor, Pfizer, manufacturing compliance, recalls
Pfizer has been forced to recall another 19,000 bottles of its cholesterol-lowering drug Lipitor in the US after consumers reported …
Pfizer withdraws hypertension drug Thelin
December 14, 2010Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
Pfizer: WikiLeaks claims “preposterous”
December 10, 2010Research and Development Nigeria, Pfizer, Trovan, WikiLeaks, ceftriaxone, clinical trial safety, industry reputation
Pfizer has dimissed as “preposterous” the claims it hired investigators to uncover evidence of corruption by a top government official …
Double blow to Pfizer’s emerging markets strategy
December 10, 2010Business Services, Sales and Marketing David Simmons, Ian Read, Jean-Michel Halfon, Jeffrey Kindler, Pfizer, Steve Yang, emerging pharma markets, recruitment
Pfizer has lost two senior executives with key roles in its emerging markets strategy. The departure of the company’s head …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Trial hitch for Pfizer’s leukaemia drug submission plans
December 7, 2010Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia
Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …
Surprise exit for Pfizer chief executive Jeffrey Kindler
December 6, 2010Manufacturing and Production, Research and Development, Sales and Marketing Ian Read, Jeffrey Kindler, Lipitor, Pfizer, Wyeth, executive succession
Pfizer’s chief executive Jeffrey Kindler has unexpectedly stepped down, saying his time at the helm of the world’s largest pharmaceutical …
Digital Pharma: Pfizer expands online clinic and aims for viral hit
November 29, 2010Medical Communications Digital Pharma blog, ManMOT, Pfizer, patient information
Pfizer’s digital initiative targeting men who are reluctant to visit a GP is to be extended until May next year …
Pfizer submits Gaucher drug to EMA
November 29, 2010Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa
Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …
The renal cell carcinoma market: Votrient to challenge Sutent’s lead
November 25, 2010Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma
After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
Brain cancer vaccine to move into phase III
November 24, 2010Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma
Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …
Pfizer’s axitinib impresses in head-to-head trial with Nexavar
November 22, 2010Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma
Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
Pfizer establishes new US research network
November 17, 2010Research and Development, Sales and Marketing BiodiscoveryTherapeutics, MedImmune, Pfizer
Pfizer has established a new network of research partnerships with its Global Centers for Therapeutic Innovation. The Centers is a …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
